Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 783-790

  Keir, Stephen T ^a   Maris, John M ^b   Reynolds, C Patrick ^c   Kang, Min H ^c   Kolb, E Anders ^d   Gorlick, Richard ^e   Lock, Richard ^f   Carol, Hernan ^f   Morton, Christopher L ^g   Wu, Jianrong ^g   Kurmasheva, Raushan T ^h   Houghton, Peter J ^h   Smith, Malcolm A ⁱ  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Developmental therapeutics; Preclinical testing; Temodar

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; EWING SARCOMA; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUMOR; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; RHABDOMYOSARCOMA; TUMOR MODEL; TUMOR XENOGRAFT;

EID: 84874957909     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24368     Document Type: Article

References (66)

1. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother Pharmacol 2009;64:647-655; Epub 2009/06/23.
2. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-291; Epub 1992/02/01.
3. Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: A review. Cancer. 2010; 454-462; Epub 2010/09/17.
4. Tisdale MJ. Antitumor imidazotetrazines-XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 1987;36:457-462; Epub 1987/02/15.
5. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-341; Epub 1998/08/04.
6. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle (Georgetown, Tex.) 2010;9:168-178; Epub 2009/12/18.
7. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007;26:186-197; Epub 2006/07/05.
8. Gerson SL. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev 2004;4:296-307; Epub 2004/04/02.
9. Pollack IF, Hamilton RL, Sobol RW, et al. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: A report from the Children's Oncology Group. Pediatr Blood Cancer 2010;55:1066-1071; Epub 2010/07/01.
10. Tentori L, Leonetti C, Aquino A. Temozolomide reduces the metastatic potential of Lewis lung carcinoma (3LL) in mice: Role of alpha-6 integrin phosphorylation. Eur J Cancer 1995;31A:746-754; Epub 1995/01/01.
11. Sampson JH, Archer GE, Villavicencio AT, et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 1999;5:1183-1188; Epub 1999/06/03.
12. Koc ON, Reese JS, Davis BM, et al. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1, 3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1, 3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum Gene Ther 1999;10:1021-1030; Epub 1999/05/01.
13. Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000;6:998-1007; Epub 2000/03/31.
14. Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: An evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 1997;40:266-272; Epub 1997/01/01.
15. Middleton MR, Kelly J, Thatcher N, et al. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 2000;85:248-252; Epub 2000/01/11.
16. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-5852; Epub 1987/11/15.
17. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997;57:2933-2936; Epub 1997/07/15.
18. Plowman J, Waud WR, Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1, 3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1994;54:3793-3799; Epub 1994/07/15.
19. Dolan ME, McRae BL, Ferries-Rowe E, et al. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res 1999;5:2059-2064; Epub 1999/09/03.
20. Reni M, Ferreri AJ, Landoni C, et al. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 2000;92:575-576; Epub 2000/04/06.
21. Bunn PA, Jr., Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592-602; Epub 1994/10/15.
22. Woll PJ, Crowther D, Johnson PW, et al. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 1995;72:183-184; Epub 1995/07/01.
23. Piccioni D, D'Atri S, Papa G, et al. Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 1995;7:224-229; Epub 1995/06/01.
24. D'Atri S, Piccioni D, Castellano A, et al. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Ann Oncol 1995;6:389-393; Epub 1995/04/01.
25. Horton TM, Thompson PA, Berg SL, et al. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: A Children's Oncology Group Study. J Clin Oncol 2007;25:4922-4928.
26. Moore MJ, Feld R, Hedley D, et al. A phase II study of temozolomide in advanced untreated pancreatic cancer. Invest New Drugs 1998;16:77-79; Epub 1998/09/18.
27. Sunkara U, Walczak JR, Summerson L, et al. A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2004;24:37-41; Epub 2004/02/26.
28. Chan AT, Leung TW, Kwan WH, et al. Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol 1998;42:247-249; Epub 1998/07/31.
29. Woll PJ, Judson I, Lee SM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999;35:410-412; Epub 1999/08/17.
30. O'Shaughnessy JA. Oral alkylating agents for breast cancer therapy. Drugs 1999; 58 1-9; Epub 2000/03/11.
31. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): A phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 2006;17:952-956; Epub 2006/03/28.
32. Myatt N, Cree IA, Kurbacher CM, et al. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 1997;8:756-762; Epub 1997/12/13.
33. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) 1995;9:1149-1158; discussion 63-64, 67-68; Epub 1995/11/01.
34. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-151; Epub 2000/05/05.
35. Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003;21:2551-2557; Epub 2003/06/28.
36. Mrugala MM, Adair J, Kiem HP. Temozolomide: Expanding its role in brain cancer. Drugs Today (Barc) 2010;46:833-846; Epub 2011/01/13.
37. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003; Epub 2005/03/11.
38. Keshelava N, Frgala T, Krejsa J, et al. DIMSCAN: A microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005;110:139-153.
39. Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharmaceut Stat 2011;10:128-134.
40. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988;48:4189-4195.
41. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-3914.
42. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940.
43. Zhang J, Stevens MF, Laughton CA, et al. Acquired resistance to temozolomide in glioma cell lines: Molecular mechanisms and potential translational applications. Oncology 2010;78:103-114; Epub 2010/04/02.
44. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-2597; Epub 2000/07/29.
45. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-3736; Epub 2004/06/03.
46. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. British J Cancer 1999;81:1022-1030; Epub 1999/11/27.
47. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 1998;78:652-661; Epub 1998/09/23.
48. Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group. J Clin Oncol 1998;16:3037-3043; Epub 1998/09/17.
49. Ogura M, Todo T, Tanaka M, et al. Temozolomide may induce therapy-related acute lymphoblastic leukaemia. Br J Haematol 2011;154:663-665; Epub 2011/04/27.
50. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer 2007;110:1542-1550; Epub 2007/08/21.
51. Verschuur AC, Grill J, Lelouch-Tubiana A, et al. Temozolomide in paediatric high-grade glioma: A key for combination therapy? Br J Cancer 2004;91:425-429; Epub 2004/07/22.
52. Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: A report from the Children's Oncology Group. Neuro Oncol 2011;13:317-323; Epub 2011/02/23.
53. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group. Neuro Oncol 2011;13:410-416; Epub 2011/02/25.
54. De Sio L, Milano GM, Castellano A, et al. Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 2006;47:30-36; Epub 2005/07/28.
55. Rubie H, Chisholm J, Defachelles AS, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol 2006;24:5259-5264; Epub 2006/11/23.
56. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118; Epub 2000/10/29.
57. Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2011;29:208-213; Epub 2010/12/01.
58. Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271-5276; Epub 2006/11/23.
59. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approach to neuroblastoma therapy consortium study. J Clin Oncol 2009;27:1290-1296; Epub 2009/01/28.
60. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:1029-1034; Epub 2009/07/29.
61. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139; Epub 2005/12/01.
62. Panetta JC, Kirstein MN, Gajjar A, et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 2003;52:435-441; Epub 2003/09/19.
63. Meany HJ, Warren KE, Fox E, et al. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 2009;65:137-142; Epub 2009/05/12.
64. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997;3:1093-1100; Epub 1997/07/01.
65. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;17:2604-2613; Epub 1999/11/24.
66. Britten CD, Rowinsky EK, Baker SD, et al. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 1999;5:1629-1637; Epub 1999/08/03.